Exploring Undiscovered Gems In India July 2024
In This Article:
Amidst a backdrop of recent selloffs and heightened volatility in the Indian stock market, investors are navigating through a phase marked by valuation concerns and economic uncertainties. As the Sensex and Nifty 50 show signs of strain, exploring undiscovered gems could potentially offer unique opportunities in such turbulent times. In this context, understanding the resilience and growth potential of smaller companies becomes crucial, especially when broader market sentiments are mixed and traditional triggers seem exhausted.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| 3B Blackbio Dx | 0.38% | 3.93% | 3.59% | ★★★★★★ |
| NGL Fine-Chem | 12.35% | 15.70% | 9.76% | ★★★★★★ |
| Le Travenues Technology | 8.99% | 36.48% | 63.83% | ★★★★★★ |
| Knowledge Marine & Engineering Works | 35.48% | 46.55% | 46.96% | ★★★★★★ |
| Indo Tech Transformers | 2.30% | 20.60% | 62.92% | ★★★★★☆ |
| Avantel | 10.67% | 34.84% | 36.61% | ★★★★★☆ |
| Spright Agro | 0.58% | 83.13% | 86.22% | ★★★★★☆ |
| KP Green Engineering | 13.73% | 47.60% | 61.28% | ★★★★★☆ |
| Apollo Micro Systems | 38.17% | 7.94% | 2.46% | ★★★★☆☆ |
| SG Mart | 16.73% | 99.32% | 94.08% | ★★★★☆☆ |
Here's a peek at a few of the choices from the screener.
Ethos
Simply Wall St Value Rating: ★★★★★★
Overview: Ethos Limited operates a chain of luxury watch boutiques across India, with a market capitalization of ?79.97 billion.
Operations: The company generates its revenue primarily through the trading of watches, accessories, and other luxury items. It has demonstrated a notable increase in gross profit margin over recent years, reaching 30.09% as of the latest report in 2024 from an earlier figure of around 25.06% in 2015. This growth indicates an improving efficiency in managing the cost of goods sold relative to sales revenue.
Ethos, a rising gem in India's specialty retail sector, outpaced its industry with a 38.1% earnings growth last year against the industry’s 28.7%. The company forecasts a robust annual earnings growth of 25.6%. Impressively, Ethos has reduced its debt-to-equity ratio from 59.1% to just 0.8% over five years, indicating strong financial health and management efficacy. Recent results underscore this trend: Q4 sales surged to INR 2,525 million from INR 2,076 million year-over-year, with net income jumping to INR 210 million from INR 133 million.
-
Dive into the specifics of Ethos here with our thorough health report.
-
Gain insights into Ethos' past trends and performance with our Past report.
Orchid Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Orchid Pharma Limited is a pharmaceutical company based in India, specializing in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals with a market capitalization of ?69.48 billion.